Kalaris Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Berkeley Heights, NJ
KLRS chart
What traders are saying about $KLRS
Latest postsKalaris Therapeutics, Inc. news
- Kalaris Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- Kalaris Therapeutics (KLRS) Tops Q3 EPS by 6c
StreetInsider ·
- Form 8K Kalaris Therapeutics Inc For: 10 November By Investing.com
Investing.com Canada ·
- KLRS: Kalaris Therapeutics Inc. filed SEC Form 8-K: Results of...
Quantisnow ·
- Kalaris Therapeutics Updates TH103 Phase 1b/2 Timeline, Completes Manufacturing Tech Transfer, and Reports Q3 2026 Results
Quiver Quantitative ·
- BRIEF-Kalaris Therapeutics Inc Q3 Operating Income USD -11.811 Million
TradingView ·
- Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Kalaris Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
TradingView ·
- Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance ·
- Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Yahoo Finance ·
- Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Yahoo Finance ·
- Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Yahoo Finance ·
Kalaris Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$43.4M | -$69.2M | -$190.4M | -$168.7M |
| Diluted EPS | $-2.85 | $-51.77 | $-42.09 | $-2.20 |
| Total assets (year end) | $121.7M | $6.2M | $190.8M | $277.1M |
| Cash and equivalents (year end) | $98.1M | $1.6M | $90.1M | $106.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Kalaris Therapeutics, Inc.
- Ticker
- KLRS (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Berkeley Heights, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1754068
- Former names
- Allovir, Inc., ViraCyte, Inc.
Frequently asked questions
What exchange is Kalaris Therapeutics, Inc. listed on?
Kalaris Therapeutics, Inc. trades on the Nasdaq under the ticker symbol KLRS.
What industry is Kalaris Therapeutics, Inc. in?
Kalaris Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Kalaris Therapeutics, Inc. headquartered?
Kalaris Therapeutics, Inc.'s business address on file with the SEC is in Berkeley Heights, NJ.
When does Kalaris Therapeutics, Inc.'s fiscal year end?
Kalaris Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Kalaris Therapeutics, Inc. report?
Kalaris Therapeutics, Inc. reported $165,000 in revenue for calendar year 2019, according to its SEC filings.